Physician profile
Firas Alani
NPI 1700833514
$6,142.73
in general payments reported to CMS, 2019-2025
21 companies · $14.81 in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,005 · 2020: $44.72 · 2021: $111 · 2024: $4,967 · 2025: $14.81.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,000 · Travel and Lodging: $1,586 · Food and Beverage: $396.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,000.00 |
| Travel and Lodging | $1,586.00 |
| Food and Beverage | $395.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan INC. | $4,949.00 | 2024 | |
| Edwards Lifesciences Corporation | $247.13 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $143.28 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $132.55 | 2019 | |
| Bard Peripheral Vascular, INC. | $126.22 | 2019 | |
| Boston Scientific Corporation | $85.61 | 2019-2024 | Watchman Flx |
| Novartis Pharmaceuticals Corporation | $82.58 | 2019-2020 | |
| Getinge USA Sales, LLC | $64.10 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $46.47 | 2019 | |
| Sanofi-Aventis U.S. LLC | $37.50 | 2019 | |
| Cardiovascular Systems INC. | $35.10 | 2019 | |
| Portola Pharmaceuticals, LLC | $34.79 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $31.61 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $24.18 | 2019 | |
| Pfizer INC. | $22.11 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $19.64 | 2019 | |
| Lundbeck LLC | $16.89 | 2019 | |
| Biosense Webster, INC. | $15.31 | 2019 | |
| Cook Medical LLC | $14.81 | 2025 | Cook Celect |
| Medtronic Vascular, INC. | $13.85 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Firas Alani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.